PRE-MARKET MOVERS

 

UPGRADES
3. LOXO:$LOXO upgraded to Buy from Neutral at Citi. PT $86 from $45
5. XOM:$XOM upgraded to Sector Outperform @ Scotia Howard Weil interesting as XOM breaking Sup at $80 with room to $75-77 on downside

 

DOWNGRADES
2. ECYT:Wedbush downgrades $ecyt from outperform to neutral & $2 PT.

 

EARNINGS

 

Trending Social Alerts
3. JUNO:$JUNO JCAR017 50% CR rate at 3 months in DLBCL. They’re back. #ASCO17
6. LOXO:$LOXO upgraded to Buy from Neutral at Citi. PT $86 from $45
7. GLYC:$GLYC presents encouraging data from Ph1/2 trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO
12. JNJ:Old prostate cancer CW: Xtandi > Zytiga. #ASCO17 CW: Zytiga > Xtandi $JNJ $PFE David Hung: ‍♂️

 

Trending News Headlines
1. Press Release | Blueprint Medicines

CAMBRIDGE, Mass. , June 5, 2017 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data and outlined registration plans for BLU-285, a potent and highly selective PDGFRα and KIT inhibitor in development as a potential treatment for patients with advanced gastrointestinal stromal tumors (GIST). In patients with PDGFRα-driven GIST harboring a D842 mutation, the data showed an objective response rate (ORR) of 60 percent and an estimated 9-month progression free survival (PFS) of 87 percent. Among patients with treatment-resistant KIT-driven GIST, tumor reduction was observed in eight of 14 evaluable patients treated at dose levels of at least 300 mg once daily (QD). BLU-285 was well tolerated, and most adverse events (AEs) reported by investigators were Grade 1 or 2. The data will be presented today in an oral presentation during the “GIST: Imatinib and Beyond” session from 1:15 to 2:45 p.m. CT (Abstract 11011) at the 2017 ASCO Annual Meeting in Chicago .

2. Aurinia Presents Additional Data from Phase Iib Aura-Lv Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company fo

3. Akebia Prevails in Two Additional European Patent Disputes

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease t

4. APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). | 2017 ASCO Annual Meeting Abstracts

LBA500 APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). Gunter Von Minckwitz, Marion Jennifer Procter, Evandro De Azambuja, Dimitrios Zardavas, Adam Knott, Giuseppe Viale, Thomas M. Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Mark Benyunes, Istvan Lang, Christelle Levy, Denise A. Yardley, Jose Bines, Richard D. Gelber, Martine J. Piccart-Gebhart, Jose Baselga; German Breast Group (GBG), Neu-Isenburg, Germany; Frontier Science (Scotland) Ltd., Kingussie, United Kingdom; Institut Jules Bordet, Brussels, Belgium; Breast International Group, Brussels, Belgium; Roche Products, Ltd., Welwyn, United Kingdom; Department of Pathology, European Institute of Oncology and University of Milan, Milan, Italy; University Hospital Bern, Bern, Switzerland; Genentech, Inc., San Francisco, CA; National Institute of Oncology, Budapest, Hungary; Centre François Baclesse, Caen, France; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; National Cancer Institute, Rio de Janeiro, Brazil; Dana-Farber Cancer Institute, Boston, MA; Jules Bordet Institute, Brussels, Belgium; Memorial Sloan Kettering Cancer Center, New York, NY

5. Andy Biotech on Twitter

“$JUNO some mixed stock reaction looks like due to another patient death”

6. Insys Therapeutics, Inc. Releases Statement on Its Ongoing Mission

PHOENIX, June 05, 2017 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ: INSY ) (“Insys” or “the Company”) issued a response to the recent media reports that highlight concerns with the Company’s past commercial practices and former employees. Insys reiterates its commitment to:

7. Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer

Clinical Trial Data for Combination of Epacadostat and Opdivo (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head an

8. What to expect from WWDC 2017

It’s that time of year again. Thousands of developers are set to descend upon the South Bay to get their software on. And the rest of the Apple watching world..

9. Press Release | Investor Relations | Bluebird Bio

– 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 10 6 ) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% –

10. Oil prices dip on fears Middle East spat could harm OPEC cuts

Oil prices reversed gains to trade down on Monday on concerns that the cutting of ties with Qatar by top crude exporter Saudi Arabia and other Arab states could hamper a global deal to reduce oil production.

11. bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

bluebird bio, Inc. (NASDAQ:BLUE), and Celgene Corporation (NASDAQ:CELG) today announced that updated results from the ongoing CRB-401 Phase 1 clinical

12. Bristol-Myers Squibb’s Opdivo, Yervoy put the brakes on mesothelioma in phase 2 | FiercePharma

New data suggest immunotherapy could stall mesothelioma progression—and that when it comes to Bristol-Myers Squibb’s checkpoint inhibitors, two might be better than one.

13. European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology

SAN FRANCISCO, June 05, 2017 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN ), a science-based biopharmaceutical company, announced today that a FibroGen European patent relating to the therapeutic use of certain small molecule inhibitors of hypoxia-inducible factor (HIF) prolyl hydroxylase was maintained by the European Patent Office.

Technology News
    Where free collaborative software projects were once the flags flown by indie developers bucking corporate computing today even companies like Exxon Mobil and Wells Fargo are releasing their own open source tools.
    Beyond the consequences for open source projects themselves the diversity problem could actually make the larger tech entrenched imbalances worse.
    One thing many respondents said drives them away from open source projects are negative interactions such as rudeness stereotyping the more extreme end of the and outright harassment.
    Where free collaborative software projects were once the flags flown by indie developers bucking corporate computing today even companies like Exxon Mobil and Wells Fargo are releasing their own open source tools.
    Beyond the consequences for open source projects themselves the diversity problem could actually make the larger tech entrenched imbalances worse.
    One thing many respondents said drives them away from open source projects are negative interactions such as rudeness stereotyping the more extreme end of the and outright harassment.
    The number of layers is carefully constrained so the mobile graphics processor can achieve the fast frame rates needed for smooth animation and user interaction with very low power usage.
    The challenge was that replacing the file system with a completely new implementation that provides major new functionality while at the same time appearing essentially unchanged to the vast array of existing software is an incredibly daunting task.
    Especially because key Windows core engineering was busy with other efforts security and WinFS was built as a component that would sit on the side and provide additional functionality for searching and rich queries.
    The number of layers is carefully constrained so the mobile graphics processor can achieve the fast frame rates needed for smooth animation and user interaction with very low power usage.
    The challenge was that replacing the file system with a completely new implementation that provides major new functionality while at the same time appearing essentially unchanged to the vast array of existing software is an incredibly daunting task.
    Especially because key Windows core engineering was busy with other efforts security and WinFS was built as a component that would sit on the side and provide additional functionality for searching and rich queries.
    In May they posed for photos at a cosplay conference in Japan dressed as a character from the game Metal Gear Solid complete with identical bikini tops ripped black tights and ammunition belts.
    While Luckey became a tech icon for reviving interest in virtual reality his politics burst into view in September when The Daily Beast published an article saying he had quietly funded a nonprofit Nimble America.
    Those familiar with the plan say Luckey believes his system which can be mounted on telephone poles can be built far more cost effectively than proposed wall on the Mexican border and with fewer obstacles from landowners.
    ET Interest in bitcoin has been skyrocketing again as the price of the digital currency has hit new highs.
    That only helps bitcoin startups in the eyes of investors.
    One of these startups Coinbase is in talks with potential investors on a new round of funding at a valuation of more than billion according to people familiar with the matter.
    When early efforts to turn around business and spin off the Alibaba shares failed to bear fruit another hedge fund manager Jeffrey Smith of Starboard Value led a campaign to push for her ouster.
    Mayer has come under more scrutiny than most Silicon Valley chief executives in part because of the Superwoman image she cultivated in an industry dominated by men the computer scientist and tireless manager who still wrote code for fun while raising three young children and looking stylish in Oscar de la Renta.
    The DNA and technology were built around its original identity as a web portal a powerful position in the early but increasingly outmoded in the mobile era as apps and phone platforms like iOS and Android became the gateways to the internet.
    In May they posed for photos at a cosplay conference in Japan dressed as a character from the game Metal Gear Solid complete with identical bikini tops ripped black tights and ammunition belts.
    While Luckey became a tech icon for reviving interest in virtual reality his politics burst into view in September when The Daily Beast published an article saying he had quietly funded a nonprofit Nimble America.
    Those familiar with the plan say Luckey believes his system which can be mounted on telephone poles can be built far more cost effectively than proposed wall on the Mexican border and with fewer obstacles from landowners.
    One of challenges is to balance attracting outside investors with its interest in supporting existing teams that have helped grow League of Legends to where it is today.
    too risky said Jace Hall the chief executive officer of Echo Fox which currently competes in League Championship Series LCS.
    And in league the rich get richer Teams that perform better will receive a larger share of revenue which will come largely from the million streaming deal it signed with BAMTech last year.
    When early efforts to turn around business and spin off the Alibaba shares failed to bear fruit another hedge fund manager Jeffrey Smith of Starboard Value led a campaign to push for her ouster.
    Mayer has come under more scrutiny than most Silicon Valley chief executives in part because of the Superwoman image she cultivated in an industry dominated by men the computer scientist and tireless manager who still wrote code for fun while raising three young children and looking stylish in Oscar de la Renta.
    The DNA and technology were built around its original identity as a web portal a powerful position in the early but increasingly outmoded in the mobile era as apps and phone platforms like iOS and Android became the gateways to the internet.

 

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Share This

Share this post with your friends!